Dana-Farber Cancer Institute researchers unveiled a platform to systematically discover molecular glue degraders, targeting a broader set of E3 ligases for cancer therapy development. The Nature paper describes a scalable screen strategy that enabled discovery of a metabolically activated molecular glue degrader, suggesting the “glue” effect can be conditional on cellular context. The work builds on the broader molecular glue paradigm that links an E3 ligase to a disease-associated protein for ubiquitination and degradation, a strategy often seen as complementary to traditional small-molecule inhibition. Investigators highlighted that most clinical degraders have leveraged only a small subset of human E3 ligases, leaving a large opportunity space. By reporting a new DCAF11-dependent degrader activated by glutathionylation, the team underscores both potential tunability and the importance of biochemical context in degrader design. The platform is positioned as an approach to accelerate candidate discovery across more targets and pathways.